Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Cowan

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
International Journal of Clinical Practice. Supplement|April 1, 2003
Buprenorphine: new pharmacological aspectsAlan Cowan
Australian Family Physician|October 19, 2004
Anal itchAlan Cowan
Journal of Addiction Medicine|July 20, 2011
Buprenorphine: the basic pharmacology revisitedAlan Cowan
European Journal of Pharmacology|October 13, 2004
Kappa opioid agonists suppress chloroquine-induced scratching in miceSaadet Inan, Alan Cowan
Handbook of Experimental Pharmacology|December 9, 2020
Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to HumansSaadet Inan, Alan Cowan
Handbook of Experimental Pharmacology|June 20, 2015
PrefaceAlan Cowan, Gil Yosipovitch
Current Neuropharmacology|November 11, 2008
Buprenorphine: a unique drug with complex pharmacologyKabirullah Lutfy, Alan Cowan
Pharmacology, Biochemistry, and Behavior|August 22, 2006
Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in ratsSaadet Inan, Alan Cowan
European Journal of Pharmacology|August 2, 2005
Reduced kappa-opioid activity in a rat model of cholestasisSaadet Inan, Alan Cowan
Neuroscience Letters|February 18, 2006
Modulation of delta opioid-evoked hypothermia in rats by WAY 100635 and fluoxetineScott M Rawls, Alan Cowan
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
International Journal of Clinical Practice. Supplement|April 1, 2003
Buprenorphine: new pharmacological aspectsAlan Cowan
Australian Family Physician|October 19, 2004
Anal itchAlan Cowan
Journal of Addiction Medicine|July 20, 2011
Buprenorphine: the basic pharmacology revisitedAlan Cowan
European Journal of Pharmacology|October 13, 2004
Kappa opioid agonists suppress chloroquine-induced scratching in miceSaadet Inan, Alan Cowan
Handbook of Experimental Pharmacology|December 9, 2020
Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to HumansSaadet Inan, Alan Cowan
Handbook of Experimental Pharmacology|June 20, 2015
PrefaceAlan Cowan, Gil Yosipovitch
Current Neuropharmacology|November 11, 2008
Buprenorphine: a unique drug with complex pharmacologyKabirullah Lutfy, Alan Cowan
Pharmacology, Biochemistry, and Behavior|August 22, 2006
Nalfurafine, a kappa opioid receptor agonist, inhibits scratching behavior secondary to cholestasis induced by chronic ethynylestradiol injections in ratsSaadet Inan, Alan Cowan
European Journal of Pharmacology|August 2, 2005
Reduced kappa-opioid activity in a rat model of cholestasisSaadet Inan, Alan Cowan
Neuroscience Letters|February 18, 2006
Modulation of delta opioid-evoked hypothermia in rats by WAY 100635 and fluoxetineScott M Rawls, Alan Cowan
Pageof 6